DelveInsight’s, “Endometriosis – Pipeline Insight, 2020,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Endometriosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Endometriosis: Overview
Endometriosis is a disease in which the endometrium (the tissue that lines the inside of the uterus or womb) is present outside of the uterus. Endometriosis most commonly occurs in the lower abdomen or pelvis, but it can appear anywhere in the body. Symptoms of endometriosis include lower abdominal pain, pain with menstrual periods, pain with sexual intercourse, and difficulty getting pregnant. On the other hand, some women with endometriosis may not have any symptoms at all.
The following are the most common symptoms for endometriosis, but each woman may experience symptoms differently or some may not exhibit any symptoms at all. Symptoms of endometriosis may include:
Some physicians may treat suspected endometriosis based on a woman’s symptoms or physical examination findings to see if they improve without proceeding to surgery. However, to formally diagnose endometriosis, a doctor must perform laparoscopy (surgery in which a doctor looks in the abdomen with a camera through the belly button) to visualize and biopsy suspected endometriosis lesions. Endometriosis lesions can vary in appearance.
The most conservative therapy for endometriosis is with medications. Non-steroidal anti-inflammatory medications, like ibuprofen, may help with the pain associated with endometriosis. Medications that control a woman’s hormones may also help with endometriosis pain. Some examples are oral contraceptive pills and gonadotropin releasing hormone (GnRH) agonists, the latter of which put women into a “temporary” menopause-like state.
Surgery can diagnose endometriosis, and it can also treat endometriosis via removal (excision) or burning (fulguration) of endometriosis lesions.
This segment of the Endometriosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments. It is currently in phase III stage of development.
NS-580 is being developed by Nippon Shinyaku for the treatment of Endometriosis. It is currently in phase II stage of development.
LY01007 is being developed by Luye Pharma for the treatment of Endometriosis. It is currently in phase I stage of development.
Further product details are provided in the report……..
This segment of the report provides insights about the different Endometriosis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 100+ key companies which are developing the therapies for Endometriosis. The companies which have their Endometriosis drug candidates in the most advanced stage, i.e. phase III include ObsEva /Kissei Pharmaceutical and others
DelveInsight’s report covers around 100+ products under different phases of clinical development like
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Endometriosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Endometriosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometriosis drugs.
Endometriosis Report Insights
Endometriosis Report Assessment
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Endometriosis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Endometriosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Endometriosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Endometriosis Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Linzagolix: ObsEva /Kissei Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
NS-580: Nippon Shinyaku
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
LY01007: Luye Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
• Comparative Analysis
Endometriosis Key Companies
Endometriosis Key Products
Endometriosis- Unmet Needs
Endometriosis- Market Drivers and Barriers
Endometriosis- Future Perspectives and Conclusion
Endometriosis Analyst Views
Endometriosis Key Companies
Appendix
List of Table
Table 1 Total Products for Endometriosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figure
Figure 1 Total Products for Endometriosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
• ObsEva
• Kissei Pharmaceutical
• Nippon Shinyaku
• Luye Pharma
• AbbVie
• Myovant Sciences GmbH
• Nobelpharma
• Dexa Medica Group
